Leuven, Belgium, June 16, 2016 (GLOBE NEWSWIRE) -- TiGenix NV (Euronext Brussels: TIG), an advanced biopharmaceutical company focused on developing and commercializing novel therapeutics based on proprietary platforms of allogeneic expanded stem cells, today announced that its CEO, Eduardo Bravo, has been named President of the EBE Board of Directors.
At the conclusion of its Annual General assembly, EBE, the European trade association that represents European biopharmaceutical companies of all sizes, announced the appointment of Eduardo Bravo, who had previously served as Vice President, to lead a 13 member C-level board for the 2016 - 2018 term.
According to Barbara Freischem, EBE's Executive Director, their role is to be a "representative voice for emerging bioscience and technology companies in Europe". She continued by saying that, "Mr. Bravo brings so much to our organization. Coming from the field of advanced therapies, he helps bridge the gap between the lab and personalized medicines within a thriving and innovation ecosystem".
In his role as President of the EBE Board of Directors, Mr. Bravo stated that the organization's objective for the near term is to advance the agenda of its stakeholder groups while serving as a platform for regulatory dialogue and entrepreneurial policies. "This is a very exciting time at the EBE. We are well positioned to help new initiatives and cutting-edge technologies advance biopharmaceutical pipelines toward eventual solutions for difficult-to-treat conditions and diseases," he said.
The EBE Board of Directors represents a unique combination of representatives from small, medium and large biopharmaceutical companies. "It is a pleasure to be working with such a dedicated group of senior industry leaders to support emerging sciences in the search of therapeutic solutions", Mr. Bravo concluded.
For more information, please contact:
Chief Financial Officer
T: +34 91 804 92 64
TiGenix NV (Euronext Brussels: TIG) is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells. Two products from the adipose-derived stem cell technology platform are currently in clinical development. Cx601 is in Phase III for the treatment of complex perianal fistulas in Crohn's disease patients. Cx611 has completed a Phase I sepsis challenge trial and a Phase I/II trial in rheumatoid arthritis. Effective July 31, 2015, TiGenix acquired Coretherapix, whose lead cellular product, AlloCSC-01, is currently in a Phase II clinical trial in acute myocardial infarction (AMI). In addition, the second product candidate from the cardiac stem cell-based platform acquired from Coretherapix, AlloCSC-02, is being developed in a chronic indication. TiGenix also developed ChondroCelect, an autologous cell therapy product for cartilage repair of the knee, which was the first Advanced Therapy Medicinal Product (ATMP) to be approved by the European Medicines Agency (EMA). From June 2014, the marketing and distribution rights of ChondroCelect were exclusively licensed to Sobi for the European Union (except for Finland, where it is distributed by the Finnish Red Cross Blood Service), Norway, Russia, Switzerland and Turkey, and the countries of the Middle East and North Africa. TiGenix is headquartered in Leuven (Belgium) and has operations in Madrid (Spain). For more information, please visit www.tigenix.com.
This press release may contain forward-looking statements and estimates with respect to the anticipated future performance of TiGenix and the market in which it operates. Certain of these statements, forecasts and estimates can be recognised by the use of words such as, without limitation, "believes", "anticipates", "expects", "intends", "plans", "seeks", "estimates", "may", "will" and "continue" and similar expressions. They include all matters that are not historical facts. Such statements, forecasts and estimates are based on various assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable when made but may or may not prove to be correct. Actual events are difficult to predict and may depend upon factors that are beyond the Company's control. Therefore, actual results, the financial condition, performance or achievements of TiGenix, or industry results, may turn out to be materially different from any future results, performance or achievements expressed or implied by such statements, forecasts and estimates. Given these uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of the publication of this press release. TiGenix disclaims any obligation to update any such forward-looking statement, forecast or estimates to reflect any change in the Company's expectations with regard thereto, or any change in events, conditions or circumstances on which any such statement, forecast or estimate is based, except to the extent required by Belgian law.